



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BSE/NSE

Date: 09.04.2025

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for Collaboration with Globalpharma Co. (L.L.C.) to Commercialize Oral Thin Film Products in the GCC Region.

Please find enclosed herewith the Press Release relating to Collaboration with Globalpharma Co. (L.L.C.) to Commercialize Oral Thin Film Products in the GCC Region.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

PIYUSH
SIDHESHWAR
NIKHADE

Digitally signed by PIYUSH SIDHESHWAR NIKHADE
DN: cn=PI, postalCode=440012, ou=MAHARASHTRA, street=325
MAHALAXMI APPT NAGPURDHANTOLWEST CENTRE ROAD 440012,
l=NAGPUR, o=Personal, title=325,
serialNumber=3ccdfc9c26923668e558b723602c5236d527cd9926
9e3746951cd8919eca04, pseudonym=32520221206180703459,
2.5.4.21=2e2e6e9833699999ec25716fc3b0b080401c1623dada52
93c438f9baaf78, email=CSPYUSHNIKHADE@GMAIL.COM,
cn=PIYUSH SIDHESHWAR NIKHADE
Date: 2025.04.09 14:49:46 +05'30'

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl: As above

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

PRESS RELEASE



ZIM Laboratories Limited and Globalpharma Co. (L.L.C.)

Announce Strategic Collaboration to Commercialize Oral Thin Film Products in the GCC Region.

Nagpur, India and Dubai, UAE, April 9th, 2025

ZIM Laboratories Limited (ZIM Labs or ZIM), a research-driven pharmaceutical company focused on differentiated oral solid dosage forms, has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co. (L.L.C.), a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region's premier investment entities.

This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs' proprietary Oral Thin Film technology platform, *ThinOral*®. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms.

Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations.

Sharing his views on the collaboration, **Mr. Zulfiqar Kamal**, Director Finance of ZIM Laboratories Limited, added:

“This collaboration represents a strong strategic fit and unlocks significant commercial potential for both parties. It reinforces our vision of building long-term value through global partnerships, while leveraging ZIM's R&D excellence and Globalpharma's strong regional footprint. Together, we aim to bring convenient, high-quality solutions to patients worldwide.”

The partnership marks a pivotal milestone in ZIM Labs' mission to make differentiated formulations globally accessible and reinforces its presence in the rapidly growing Middle Eastern Pharmaceutical market.

About ZIM Laboratories Limited:

ZIM Laboratories Limited (ZIM or ZIM Labs), headquartered in India, is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. With state-of-the-art in-house R&D capabilities, ZIM offers innovative drug delivery solutions using proprietary technology platforms aimed at enhancing patient convenience and treatment adherence. The shares of ZIM are listed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). For more information, visit – <https://www.zimlab.in>

About Globalpharma Co. (L.L.C.):

Globalpharma Co. (L.L.C.), a wholly owned subsidiary of Dubai Investments PJSC, is a leading pharmaceutical manufacturer in the Middle East with a strong presence across the GCC and select African markets. Established in 1998 and operational since 2003, Globalpharma has emerged as a market leader in key generic pharmaceutical segments. The company expanded significantly in 2008 through the launch of new products and product line extensions. It operates two advanced manufacturing facilities in the UAE: a state-of-the-art Beta-Lactam Penicillin plant supplying Amoxicillin and AmoxiClav across the MENA region, and a General Medicine plant catering to lifestyle disease segments with robust capabilities in liquid and oral solid dosage forms. Globalpharma is committed to delivering high-quality, affordable medicines and driving healthcare innovation across the region.

For more information, visit - <https://www.globalpharma.ae/>

For further information, please contact:

ZIM Laboratories Limited

Website: www.zimlab.in

Email: info@zimlab.in